ABN AMRO Bank N.V. Acquires Shares of 46,091 Gilead Sciences, Inc. $GILD

ABN AMRO Bank N.V. acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 46,091 shares of the biopharmaceutical company’s stock, valued at approximately $5,138,000.

Several other institutional investors and hedge funds also recently made changes to their positions in GILD. Norges Bank bought a new position in Gilead Sciences during the second quarter worth about $2,150,268,000. Ameriprise Financial Inc. boosted its holdings in Gilead Sciences by 397.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 6,748,403 shares of the biopharmaceutical company’s stock valued at $748,147,000 after purchasing an additional 5,392,191 shares during the period. Invesco Ltd. grew its position in shares of Gilead Sciences by 33.5% during the 2nd quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock worth $1,499,098,000 after purchasing an additional 3,394,330 shares in the last quarter. Assenagon Asset Management S.A. grew its position in shares of Gilead Sciences by 164.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 3,489,062 shares of the biopharmaceutical company’s stock worth $387,286,000 after purchasing an additional 2,169,266 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of Gilead Sciences by 1.6% during the second quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock worth $13,233,912,000 after purchasing an additional 1,893,401 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

GILD has been the subject of several recent research reports. Morgan Stanley cut their price target on Gilead Sciences from $151.00 to $150.00 and set an “overweight” rating for the company in a research note on Tuesday, January 13th. Wolfe Research lifted their price objective on Gilead Sciences from $150.00 to $155.00 and gave the company an “outperform” rating in a report on Wednesday, January 28th. Truist Financial increased their target price on Gilead Sciences from $140.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday, January 27th. Sanford C. Bernstein set a $135.00 price target on Gilead Sciences and gave the stock an “outperform” rating in a research report on Monday, December 29th. Finally, Wall Street Zen downgraded Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, January 23rd. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $136.73.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $146.23 on Thursday. The company has a market capitalization of $181.42 billion, a price-to-earnings ratio of 22.67, a PEG ratio of 0.76 and a beta of 0.36. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. Gilead Sciences, Inc. has a twelve month low of $93.37 and a twelve month high of $146.73. The stock has a fifty day simple moving average of $126.41 and a 200 day simple moving average of $120.40.

Insider Transactions at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $125.86, for a total value of $3,524,080.00. Following the completion of the sale, the insider directly owned 107,193 shares in the company, valued at $13,491,310.98. This trade represents a 20.71% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction on Friday, November 28th. The stock was sold at an average price of $125.08, for a total value of $625,400.00. Following the completion of the transaction, the director owned 8,920 shares in the company, valued at approximately $1,115,713.60. This represents a 35.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 257,397 shares of company stock worth $33,385,512. Corporate insiders own 0.27% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.